Following the successful IPO, Draupnir Holding B.V (as the selling shareholder) granted and funded (or reimbursed, as the case may be) a bonus to eligible members of the Board of Directors and the Executive Committee as well as other eligible employees and a former director of PolyPeptide Laboratories Holding B.V. (the Group’s predecessor holding company) in recognition of their past efforts to the Group. The IPO Recognition Bonus was paid in cash; however, eligible members of the Board of Directors, the Executive Committee and certain other senior managers received 50% of their IPO Recognition Bonus in shares.
The EGM 2021 approved the IPO Recognition Bonus in a cumulative amount of EUR 7.0 million (excluding social security costs, etc.), of which the following amounts set forth in the table below were paid and/or granted to eligible members of the Board of Directors and the Executive Committee as well as other eligible employees and a former director of PolyPeptide Laboratories Holding B.V. (the Group’s predecessor holding company). All costs, including additional associated costs (e.g., social security contributions), were fully reimbursed by Draupnir Holding B.V. (i.e., the Company did not incur any costs or make any additional contributions in association with the IPO Recognition Bonus).
|
EUR |
Cash compensation |
Share-based compensation |
Total (cash and shares) |
Social security and other contributions 5 |
Total IPO Recognition Bonus |
|
|
|
|
|
|
|
|
Erik Schropp 1 |
185,000 |
185,000 |
370,000 |
– |
370,000 |
|
Jane Salik 2 |
1,000,000 |
1,000,000 |
2,000,000 |
17,608 |
2,017,608 |
|
Jan Fuhr Miller 3 |
450,000 |
450,000 |
900,000 |
7,924 |
907,924 |
|
Jan Christensen 3 |
450,000 |
450,000 |
900,000 |
460,884 |
1,360,884 |
|
Daniel Lasanow 3 |
450,000 |
450,000 |
900,000 |
477,770 |
1,377,770 |
|
Other employees 4 |
1,485,000 |
445,000 |
1,930,000 |
516,818 |
2,446,818 |
|
Total |
4,020,000 |
2,980,000 |
7,000,000 |
1,481,004 |
8,481,004 |